Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib for FGFR1 Amplified Squamous NSCLC
NCT01861197Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Mar 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in squamous cell carcinoma of the lung (SCCL), sponsored by Samsung Medical Center. Primary endpoint: Overall Response Rate at 6 months. Status: unknown.
02
Drugs
dovitinib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT01861197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861197.